$BDTX
Black Diamond Therapeutics Inc Stock $bdtx

$bdtx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000170154123000041 Filed on August 11, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.860M	$6.878M
YoY Change	25.22%	-1.43%
% of Gross Profit
Research & Development	$16.15M	$13.15M
YoY Change	1.94%	-18.78%
% of Gross Profit
Depreciation & Amortization	$110.0K	$114.0K
YoY Change	-14.73%	-10.94%
% of Gross Profit
Operating Expenses	$24.01M	$20.03M
YoY Change	8.53%	-13.55%
Operating Profit	-$24.01M	-$20.03M
YoY Change	8.53%	-13.55%
Interest Expense	$440.0K	$539.0K
YoY Change	-21.71%	39.64%
% of Operating Profit
Other Income/Expense, Net	$1.005M	$880.0K
YoY Change	113.83%	262.14%
Pretax Income	-$23.01M	-$19.15M
YoY Change	6.26%	-16.48%
Income Tax
% Of Pretax Income
Net Earnings	-$23.01M	-$19.15M
YoY Change	6.25%	-16.48%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.45	-$0.52
Diluted Earnings Per Share	-$0.45	-$0.52
COMMON SHARES
Basic Shares Outstanding	51.58M shares	36.51M shares
Diluted Shares Outstanding	50.94M shares	36.52M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$144.3M	$89.53M
YoY Change	0.05%	-44.36%
Cash & Equivalents	$57.98M	$41.89M
Short-Term Investments	$86.28M	$47.64M
Other Short-Term Assets	$2.800M	$3.465M
YoY Change	-58.81%	-54.81%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$147.0M	$92.99M
YoY Change	-2.6%	-44.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.816M	$2.253M
YoY Change	-33.5%	-21.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$800.0K	$1.228M
YoY Change		12180.0%
Total Long-Term Assets	$25.33M	$26.89M
YoY Change	-13.94%	-11.19%
TOTAL ASSETS
Total Short-Term Assets	$147.0M	$92.99M
Total Long-Term Assets	$25.33M	$26.89M
Total Assets	$172.4M	$119.9M
YoY Change	-4.45%	-39.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$694.0K	$2.737M
YoY Change	-87.95%	23.18%
Accrued Expenses	$14.37M	$11.16M
YoY Change	-6.57%	-36.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.07M	$13.90M
YoY Change	-28.74%	-29.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$23.00M	$23.78M
YoY Change	-11.68%	-11.12%
Total Long-Term Liabilities	$23.00M	$23.78M
YoY Change	-11.68%	-11.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.07M	$13.90M
Total Long-Term Liabilities	$23.00M	$23.78M
Total Liabilities	$38.07M	$37.68M
YoY Change	-19.33%	-18.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$398.0M	-$375.0M
YoY Change	26.79%	28.32%
Common Stock	$7.000K	$5.000K
YoY Change	40.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$134.3M	$82.20M
YoY Change
Total Liabilities & Shareholders Equity	$172.4M	$119.9M
YoY Change	-4.45%	-39.71%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$23.01M	-$19.15M
YoY Change	6.25%	-16.48%
Depreciation, Depletion And Amortization	$110.0K	$114.0K
YoY Change	-14.73%	-10.94%
Cash From Operating Activities	-$18.36M	-$14.37M
YoY Change	11.43%	-20.47%
INVESTING ACTIVITIES
Capital Expenditures	$30.00K	$0.00
YoY Change	275.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$37.85M	$17.18M
YoY Change	-361.05%	-14.13%
Cash From Investing Activities	-$37.88M	$17.18M
YoY Change	-361.12%	-13.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	71.93M	0.000
YoY Change	138226.92%
NET CHANGE
Cash From Operating Activities	-18.36M	-14.37M
Cash From Investing Activities	-37.88M	17.18M
Cash From Financing Activities	71.93M	0.000
Net Change In Cash	15.69M	2.807M
YoY Change	-918.47%	61.23%
FREE CASH FLOW
Cash From Operating Activities	-$18.36M	-$14.37M
Capital Expenditures	$30.00K	$0.00
Free Cash Flow	-$18.39M	-$14.37M
YoY Change	11.56%	-19.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36434297	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36434297	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.33
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36516114	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36516114	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	200000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	95000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	41886000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	57241000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20504000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	41981000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36537000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	51000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	153000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	34000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	bdtx	Increase Decrease In Right Of Use Asset Obtained In Exchange For Operating Lease Liability IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	bdtx	Increase Decrease In Right Of Use Asset Obtained In Exchange For Operating Lease Liability IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	109000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	195900000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	142000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3375000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-1361000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25507000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	172560000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3252000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-511000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-22930000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	115695000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	51000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2671000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	648000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20875000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2646000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	515000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-19152000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	82199000	usd
CY2022Q4	bdtx	Accrued Contract Research Service Fees Current AccruedContractResearchServiceFeesCurrent	4713000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2998000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4648000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1359000	usd
	us-gaap	Use Of Estimates UseOfEstimates	Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	48300000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	661000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	47639000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	90316000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1824000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	88492000	usd
CY2023Q2	bdtx	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	1994000	usd
CY2022Q4	bdtx	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	13687000	usd
CY2022	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3337000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	750000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2587000	usd
	us-gaap	Depreciation Depreciation	253000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	2232000	usd
CY2022	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	710000	usd
CY2023Q2	bdtx	Accrued Contract Research Service Fees Current AccruedContractResearchServiceFeesCurrent	3829000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1182000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2975000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2841000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11161000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13384000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2646000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3252000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5317000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6627000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2646000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3252000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5317000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6627000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5359400	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.40
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	76000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3226650	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	350424	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.61
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	68124	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	28.26
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8167502	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.51
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11313000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8167502	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.51
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	11313000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3265021	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.61
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M24D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1610000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	15169000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-19152000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-22930000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-40027000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-48437000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36516114	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36516114	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36293856	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36293856	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36500085	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36500085	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36282636	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36282636	shares
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.33
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8394723	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6539177	shares
	bdtx	Lessee Operating Lease Number Of Contracts LesseeOperatingLeaseNumberOfContracts	2	contract
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1054000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1057000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2108000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2116000	usd
CY2023Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	11000	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	21000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	28000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	40000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	126000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	219000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	382000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	476000	usd
CY2023Q2	us-gaap	Sublease Income SubleaseIncome	335000	usd
CY2022Q2	us-gaap	Sublease Income SubleaseIncome	0	usd
	us-gaap	Sublease Income SubleaseIncome	470000	usd
	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	856000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	1297000	usd
	us-gaap	Lease Cost LeaseCost	2048000	usd
	us-gaap	Lease Cost LeaseCost	2632000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2103000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1290000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2141000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4359000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4477000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4599000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4724000	usd
CY2023Q2	bdtx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	12250000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	32550000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5793000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	26757000	usd
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2023Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	167000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	543000	usd
CY2022Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	199000	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	757000	usd

Files In Submission

Name	View Source	Status
0001701541-23-000041-index-headers.html	Edgar Link	pending
0001701541-23-000041-index.html	Edgar Link	pending
0001701541-23-000041.txt	Edgar Link	pending
0001701541-23-000041-xbrl.zip	Edgar Link	pending
bdtx-20230630.htm	Edgar Link	pending
bdtx-20230630.xsd	Edgar Link	pending
exhibit311_q22023.htm	Edgar Link	pending
exhibit312_q22023.htm	Edgar Link	pending
exhibit321_q22023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
bdtx-20230630_lab.xml	Edgar Link	unprocessable
bdtx-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bdtx-20230630_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bdtx-20230630_cal.xml	Edgar Link	unprocessable
bdtx-20230630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BDTX
Black Diamond Therapeutics Inc Stock $bdtx

2023 Q3 Form 10-Q Financial Statement

#000170154123000041 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDTX Black Diamond Therapeutics Inc Stock $bdtx

2023 Q3 Form 10-Q Financial Statement

#000170154123000041 Filed on August 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDTX
Black Diamond Therapeutics Inc Stock $bdtx